IP Library Patent Application 15915688
Patent Application
App. No. 15/915,688

METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS ASSOCIATED WITH POST-TRAUMATIC STRESS DISORDER USING CYCLOBENZAPRINE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/915,688
Abstract

The present invention relates to methods for the treatment or prevention of symptoms associated with post-traumatic stress disorder, and related pharmaceutical compositions. Of particular interest are pharmaceutical compositions comprising a very low dose of cyclobenzaprine, alone, or in combination with an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor.

Claims (10)

1 - 11 . (canceled)

12 . A pharmaceutical composition comprising a therapeutically effective amount of cyclobenzaprine in combination with a drug selected from the group consisting of an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor and a serotonin-norepinephrine reuptake inhibitor.

13 . The pharmaceutical composition of claim 12 , wherein the drug is prazosin or escitalopram.

14 . The pharmaceutical composition of claim 12 , wherein the amount of cyclobenzaprine is between 0.1 mg and 50 mg.

15 . The pharmaceutical composition of claim 14 , wherein the amount of cyclobenzaprine is between 0.5 mg and 30 mg.

16 . The pharmaceutical composition of claim 15 , where the amount of cyclobenzaprine is between 1 mg and 20 mg.

17 . The pharmaceutical composition of claim 12 , wherein the amount of cyclobenzaprine is less than 5 mg.

18 . The pharmaceutical composition of claim 17 , wherein the amount of cyclobenzaprine is less than 2.5 mg.

19 . The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition is an orally dissolving tablet or a thin film formulation.

20 - 76 . (canceled)

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2018
From: LEDERMAN, SETH; HARRIS, HERB
To: TONIX PHARMACEUTICALS, INC.
Reel/Frame 045535/0661 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2018
From: TONIX PHARMACEUTICALS, INC.
To: TONIX PHARMA HOLDINGS LIMITED
Reel/Frame 045535/0880 →